Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 1, 2007, Pages 35-48

  Baumeister, Judith ^a,b   Fischer, Ruediger ^a   Eckenberg, Peter ^a   Henninger, Kerstin ^a   Ruebsamen Waigmann, Helga ^a   Kleymann, Gerald ^b,c  

^a AiCuris GmbH   (Germany)

^b Virco BVBA   (Belgium)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antiviral agent; BAY 57 1293; Guinea pig; Helicase primase; HSV

Indexed keywords

ANTIVIRUS AGENT; HELICASE PRIMASE INHIBITOR; UNCLASSIFIED DRUG; VALACICLOVIR;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENITAL HERPES; HERPES; HERPES SIMPLEX VIRUS 2; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPTOMATOLOGY; VIRUS LOAD;

EID: 33947286682     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800104     Document Type: Article

References (51)

1. Benedetti JK, Zeh J & Corey L (1999) Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Annals of Internal Medicine 131:14-20.
2. Bernstein DI, Harrison CJ, Tomai MA & Miller RL (2001) Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. The Journal of Infectious Diseases 183:844-849.
3. Bernstein DI, Ireland J & Bourne N (2000) Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations. Antiviral Research 47:159-169.
4. Bernstein DI, Miller RL & Harrison CJ (1993) Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acylovir on genital HSV-2 inection in guinea-pigs when begun after lesion development. Antiviral Research 20:45-55.
5. Bernstein DI, Stanberry LR, Harrison CJ, Kappes JC & Myers MG (1986) Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. Journal of General Virology 67:1601-1612.
6. Betz UA, Fischer R, Kleymann G, Hendrix M & Rübsamen-Waigmann H (2002) Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrobial Agents and Chemotherapy 46:1766-1772.
7. Bourne N, Bernstein DI & Stanberry LR (1999a) Civamide (cis-Capsaicin) for treatment of primary or recurrent experimental genital herpes. Antimicrobial Agents and Chemotherapy 43:2685-2688.
8. Bourne N, Bravo FJ, Ashton WT, Meurer LC, Tolman RL, Karkas JD & Stanberry LR (1992) Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes. Antimicrobial Agents and Chemotherapy 36:2020-2024.
9. Bourne N, Ireland J Stanberry LR & Bernstein DI (1999b) Effect of undecylenic acid as a tropical microbicide against genital herpes infection in mice and guinea pigs. Antiviral Research 40:139-144.
10. Bravo FJ, Stanberry LR, Kier AB, Vogt PE & Kern ER (1993) Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Research 21:59-72.
11. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, Johnson L, Wiesmeier E, Growdon W, Creagh-Kirk T & Keeney R (1983) Threatment of first episodes of genital herpes simplex virus infection with oral acyclovir. The New England Journal of Medicine 308:916-921.
12. Bryson YJ, Dillon M, Lovett M, Bernstein DI, Garratty E & Sayre J (1985) Treatment of first episode genital HSV with oral acyclovir: long term follow-up of recurrences. Scandinavian Journal of Infectious Diseases Suppl 47:70-75.
13. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D & Vargas-Cortes M (2004) Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 350:11-20.
14. de Miranda P & Good SS (1992) Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antiviral Chemistry and Chemotherapy 3:1-8.
15. Diamond C, Selke S, Ashley R, Benedetti J & Corey L (1998) Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sexually Transmitted Diseases 26:221-225.
16. Efstathiou S, Field HJ, Griffiths PD, Kern ER, Sacks SL, Sawtell NM & Stanberry LR (1999) Herpes simplex virus latency and nucleoside analogues. Antiviral Research 41:85-100.
17. Fife KH, Crumpacker CS, Mertz GJ, Hill EL & Boone GS (1994) Recurrence and resistance pattern of herpes simplex virus following cessation of > or = 6 years of chronic suppression with aciclovir. Aciclovir study group. The Journal of Infectious Diseases 169:1338-1341.
18. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK & St Louis ME (1997) Herpes simplex type 2 in the United States, 1976 to 1994. The New England Journal of Medicine 337:1105-1111.
19. Jennings R, Smith TL, Myhren F, Phillips J & Sandvold ML (1999) Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes. Antimicrobial Agents and Chemotherapy 43:53-61.
20. Kern ER, Richards JT, Overall JC Jr & Glasgow LA (1978) Alteration of mortality and pathogenesis of three experimental herpesvirus hominis infections of mice with adenine arabinosede 5′-monophosphat, adenine arabinoside and phosphonoacetic acid. Antimicrobial Agents and Chemotherapy 13:53-60.
21. Kern ER (1981) Acyclovir treatment of experimental genital herpes simplex virus infection. The American Journal of Medicine 37 (1A):100-108.
22. Kern ER (1984) Treatment of genital herpes simplex virus infections in guinea pigs. New York: AR Liss Inc.
23. Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V, Baumeister J, Weber O, Henninger K, Keldenich J, Jensen A, Kolb J, Bach U, Popp P, Mäßen J, Frappa I, Haebich D, Lockhoff O & Rúbsamen-Waigmann H (2002) New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine 8:392-398.
24. Kleymann G (2004) Discovery and SAR of herpesvirus helicase primase inhibitors. Current Medicinal Chemistry 3:69-84.
25. Kleymann G (2003a) Helicase primase inhibitors. Drugs of the Future 28:257-265.
26. Kleymann G (2003b) New antiherpes drugs target viral helicase-primase enzymes. Herpes 10:46-52.
27. Kleymann G (2004) Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antiviral Chemistry and Chemotherapy 15:135-140.
28. Kleymann G (2005) Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opinion on Investigational Drugs 14:135-161.
29. Kleymann G (2006) Antiviral treatment. In Herpes simplex viruses. Edited by M. Studahl, P. Cinque, T. Bergstrom. New York, NY: Taylor & Francis Group, LLC
30. Landry ML, Lucia HL, Hsiung GD, Pronovost AD, Dann PR, August MJ & Mayo DR (1982) Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig. The American Journal of Medicine 73(1A):143-150.
31. Landry ML, Myerson D & Bull C (1992) Recurrent genital infection in the guinea pig: differences between herpes simplex types 1 and 2. Intervirology 34:169-179.
32. Lekstrom-Himes JA, Pesnicak L & Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. Journal of Virology 72:2760-2764.
33. Lukas B, Wiesendanger W & Schmidt-Ruppin KH (1974) Genital herpes in guinea pigs. Archives of Virology 44:153-155.
34. Miller RL, Imbertson LM, Reiter MJ & Gerster JF (1999) Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Research 44:31-42.
35. Mori K., Yasutomi, Y., Sawada, S, Villinger F, Sugama K, Rosenwirth, B, Heeney, J, Ueberla, K, Yamazaki, S, Ansari, A, Rubsamen-Waigmann H (2000) Suppression of actute viraemia by short-term postexposure prophylaxis of SHIV-RT infected monkeys with a novel RT-inhibitor allows for potent antiviral responses resulting in efficient containment of infection. Journal of Virology 74:5747-5753.
36. Myerson D & Hsiung GD (1983) Prophylactic and therapeutic treatment with acyclovir of genital herpes in the guinea pig. Proceedings of the Society for Experimental Biology and Medicine 174:147-152.
37. Patel R, Boselli F, Cairo I, Barnett G, Price M & Wulff HC (2001) Patient's perspective on the burden of recurrent genital disease. International Journal of STD & AIDS 12:640-645.
38. Pronovost AD, Lucia HL, Dann PR & Hsiung GD (1982) Effect of acyclovir on genital herpes in guinea Pigs. The Journal of Infectious Diseases 145:904-908.
39. Rapp F (1984) Herpesvirus: proceedings of a Burroughs Wellcome-UCLA symposium held at Steamboat Springs, Colorado April 8-13, 1984; pp. 617-636. New York: AR Liss Inc.
40. Roizman B & Knipe DM (2006) Herpes simplex viruses and their replication infields Virology, 5th ed, vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins.
41. Scott LL, Hollier LM & Dias K (1997) Perinatal herpesvirus infections. Herpes simplex, varicella and cytomegalovirus. Infectious Disease Clinics of North America 11:27-53.
42. Stanberry LR, Kern ER, Richards JT, Abbott TM & Overall JC (1982) Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. The Journal of Infectious Diseases 146:397-404.
43. Stanberry LR (1994) Animal models and HSV latency. Seminars in Virology 5:213-219.
44. Stanberry LR, Kern ER, Richards JT & Overall JC (1985) Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24:226-231.
45. Szczech GM (1996) Preclinical development of antiviral drugs. Clinical Infectious Diseases 22:355-360.
46. Wald A & Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type-2 seropositive persons: a meta-analysis. The Journal of Infectious Diseases 185:45-52.
47. Wald A, Zeh J, Selke S, Ashley RL & Corey L (1995) Virologic characteristics of subclinical and symptomatic genital herpes infections. The New England Journal of Medicine 333:770-775.
48. Whitley, RJ (2006) Herpes simplex viruses. In Fields Virology 5th Ed. Edited by DM Knipe & PM Howley. Philadelphia, PA: Lippincott Williams & Wilkins.
49. Whitley RJ & Roizman B (2001) Herpes simplex virus infections. Lancet 357:1513-1518.
50. Workowski KA & Berman SM (2006) Sexually transmitted diseases treatment guidelines, 2006. MMWR. Recommendations and reports 55(RR-11):1-94. Erratum in: MMWR. Recommendations and reports (2006) 55(36):997.
51. Yeung-Yue KA, Torres G, Brentjens M, Lee PC, Tyring SK (2003) Herpes Simplex Virus. In Viral Infections and Treatment, Edited by H Rübsamen-Waigmann, K Deres, G Hewlett, R Welker. New York: Marcel Dekker.